210 related articles for article (PubMed ID: 26921085)
1. Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice.
Dushenkov A; Kalabalik J; Carbone A; Jungsuwadee P
J Oncol Pharm Pract; 2017 Jun; 23(4):296-308. PubMed ID: 26921085
[TBL] [Abstract][Full Text] [Related]
2. Aprepitant and fosaprepitant drug interactions: a systematic review.
Patel P; Leeder JS; Piquette-Miller M; Dupuis LL
Br J Clin Pharmacol; 2017 Oct; 83(10):2148-2162. PubMed ID: 28470980
[TBL] [Abstract][Full Text] [Related]
3. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.
Aapro M; Carides A; Rapoport BL; Schmoll HJ; Zhang L; Warr D
Oncologist; 2015 Apr; 20(4):450-8. PubMed ID: 25795636
[TBL] [Abstract][Full Text] [Related]
4. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Controlled Pilot Study Comparing the Impact of Aprepitant and Fosaprepitant on Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecologic Cancer.
Micha JP; Rettenmaier MA; Brown JV; Mendivil A; Abaid LN; Lopez KL; Goldstein BH
Int J Gynecol Cancer; 2016 Feb; 26(2):389-93. PubMed ID: 26588232
[TBL] [Abstract][Full Text] [Related]
6. Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Ruhlmann CH; Herrstedt J
Expert Opin Drug Saf; 2011 May; 10(3):449-62. PubMed ID: 21417835
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity.
Shadle CR; Lee Y; Majumdar AK; Petty KJ; Gargano C; Bradstreet TE; Evans JK; Blum RA
J Clin Pharmacol; 2004 Mar; 44(3):215-23. PubMed ID: 14973304
[TBL] [Abstract][Full Text] [Related]
8. Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy.
Garnock-Jones KP
Drugs; 2016 Sep; 76(14):1365-72. PubMed ID: 27510503
[TBL] [Abstract][Full Text] [Related]
9. Peripheral neuropathy in non-Hodgkin's lymphoma patients receiving vincristine with and without aprepitant/fosaprepitant.
Edwards JK; Bossaer JB; Lewis PO; Sant A
J Oncol Pharm Pract; 2020 Jun; 26(4):809-813. PubMed ID: 31446866
[TBL] [Abstract][Full Text] [Related]
10. [Determination of the Effect of Aprepitant and Fosaprepitant for Nausea in Patients with Oral Cancer Receiving Combination Chemotherapy with TPF].
Uchiyama K; Yamada M; Shiiba Y; Kasazaki S; Suga K; Iwabuchi H; Asoda S; Uehara K
Gan To Kagaku Ryoho; 2017 Jul; 44(7):585-589. PubMed ID: 28790262
[TBL] [Abstract][Full Text] [Related]
11. Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Ruhlmann CH; Herrstedt J
Expert Rev Anticancer Ther; 2012 Feb; 12(2):139-50. PubMed ID: 22316362
[TBL] [Abstract][Full Text] [Related]
12. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
[TBL] [Abstract][Full Text] [Related]
13. Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy.
Ando Y; Hayashi T; Ito K; Suzuki E; Mine N; Miyamoto A; Oya M; Matsuda H; Isaji A; Nakanishi T; Imaizumi K; Shibata T; Okada T; Sakurai K; Naito K; Uyama I; Kawada K; Takahashi H; Yamada S
Support Care Cancer; 2016 Feb; 24(2):871-878. PubMed ID: 26206077
[TBL] [Abstract][Full Text] [Related]
14. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
Nishimura J; Satoh T; Fukunaga M; Takemoto H; Nakata K; Ide Y; Fukuzaki T; Kudo T; Miyake Y; Yasui M; Morita S; Sakai D; Uemura M; Hata T; Takemasa I; Mizushima T; Ohno Y; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
Eur J Cancer; 2015 Jul; 51(10):1274-82. PubMed ID: 25922233
[TBL] [Abstract][Full Text] [Related]
15. A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis.
Maru A; Gangadharan VP; Desai CJ; Mohapatra RK; Carides AD
Indian J Cancer; 2013; 50(4):285-91. PubMed ID: 24369195
[TBL] [Abstract][Full Text] [Related]
16. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
Massaro AM; Lenz KL
Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Drug-Drug Interaction between Warfarin and Aprepitant and Its Effects on PT-INR of Patients Receiving Anticancer Chemotherapy.
Takaki J; Ohno Y; Yamada M; Yamaguchi R; Hisaka A; Suzuki H
Biol Pharm Bull; 2016 May; 39(5):863-8. PubMed ID: 26948084
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects.
Marbury TC; Ngo PL; Shadle CR; Jin B; Panebianco D; Caro L; Valentine J; Murphy G
J Clin Pharmacol; 2011 Dec; 51(12):1712-20. PubMed ID: 21209230
[TBL] [Abstract][Full Text] [Related]
19. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
20. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
